Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Inflammation
Published in: Inflammation 4-6/2005

01-12-2005

Activatory Properties of Lysophosphatidic Acid on Human THP-1 Cells

Authors: F. D’Aquilio, M. Procaccini, V. Izzi, V. Chiurchiu’, V. Giambra, F. Carotenuto, P. Di Nardo, P. M. Baldini

Published in: Inflammation | Issue 4-6/2005

Login to get access

Abstract

Excessive leukocyte proliferation and proinflammatory mediators release represent common phenomena in several chronic inflammatory diseases. Multiple evidences identify lysophosphatidic acid (LPA), a small lipid endowed with pleiotropic activities, as an important modulator of both proliferation and activation of different cell types involved in several inflammation-associated pathologies. However, its possible role on monocyte proinflammatory activation is not fully understood yet. Aim of the present study was to investigate LPA effects on THP-1 cells in terms of proliferation, reactive oxygen intermediates (ROI) production and release of arachidonic acid-derived inflammatory mediators. Actually, LPA significantly increased both DNA synthesis and ROI production as well as prostaglandin E2 release and the upregulation of LPA3 receptor expression. These findings identified LPA as both a growth factor and a triggering mediator of proinflammatory response in THP-1 cells.
Literature
1.
Moolenaar, W. H. 2000. Development of our current understanding of bioactive lysophospholipids. Ann. NY Acad. Sci. 905: 1–10.PubMedCrossRef
2.
Fukushima, N., and J. Chun. 2001. The LPA receptors. Prostaglandins 64:21–32.PubMed
3.
Goetzl E. J., W. Wang, G. McGiffert, M. G. Huang, and M. H. Graler. 2004. Sphingosine 1-phosphate and its G protein-coupled receptors constitute a multifunctional immunoregulatory system. J. Cell. Biochem. 92(6):1104–1114PubMedCrossRef
4.
Graler, M. H., and E. J. Goetzl. 2002. Lysophospholipids and their G protein-coupled receptors in inflammation and immunity. Biochim. Biophys. Acta. 1582(1–3):168–174.PubMed
5.
Siess, W., K. J. Zangle, M. Essler, M. Bauer, R. Brandl, C. Corrinth, R. Bittman, G. Tigyi, and M. Aepfelbacher. 1999. Lysophosphatidic acid mediates the rapid activation of platelets and endothelial cells by mildly oxidized low density lipoprotein and accumulates in human atherosclerotic lesions. Proc. Natl. Acad. Sci. USA. 96(12):6931–6936.PubMedCrossRef
6.
Panther E., M. Idzko, S. Corinti, D. Ferrari, Y. Herouy, M. Mockenhaupt, S. Dichmann, P. Gebicke-Haerter, F. Di Virgilio, G. Girolomoni, and J. Norgauer. 2002. The influence of lysophosphatidic acid on the functions of human dendritic cells. J. Immunol. 169(8):4129–4135.PubMed
7.
Andres V., and C. Castro. 2003. Antiproliferative strategies for the treatment of vascular proliferative disease. Curr. Vasc. Pharmacol. 1:85–98.PubMedCrossRef
8.
9.
Osterud, B., and E. Bjorklid. 2003. Role of monocytes in atherogenesis. Physiol. Rev. 83(4):1069–1112.PubMed
10.
Melo, R. C., N., D. L. Fabrino, H. D’Ávila, H. C. Teixeira, and A. P. Ferreira. 2003. Production of hydrogen peroxide by peripheral blood monocytes and specific macrophages during experimental infection with Trypanosoma cruzi in vivo. Cell. Biol. Int. 27(10):853–861.PubMedCrossRef
11.
12.
Hadjigogos, K. 2003. The role of free radicals in the pathogenesis of rheumatoid arthritis. Panminerva Med. 45(1):7–13.PubMed
13.
Lu, Y., and L. M. Wahl. 2005. Oxidative stress augments the production of matrix metalloproteinase-1, cyclooxygenase-2, and prostaglandin E2 through enhancement of NF-kappa B activity in lipopolysaccharide-activated human primary monocytes. J. Immunol. 175(8):5423–5429.PubMed
14.
Vila, L. 2004. Cyclooxygenase and 5-lipoxygenase pathways in the vessel wall: role in atherosclerosis. Med. Res. Rev. 24(4):399–424.PubMedCrossRef
15.
Shen, H. M., C. Y. Shi, Y. Shen, and C. N. Ong. 1996. Detection of elevated reactive oxygen species level in cultured rat hepatocytes treated with aflatoxin B1. Free Radic. Biol. Med. 21:139–146.PubMedCrossRef
16.
Donchenko, V., A. Zannetti, and P. M. Baldini. 1994. Insulin-stimulated hydrolysis of phosphatidylcholine by phospholipase C and phospholipase D in cultured rat hepatocytes. Biochim. Biophys. Acta 1222(3):492–500.PubMedCrossRef
17.
Johann, A. M., A. von Knethen, D. Lindemann, and B. Brüne. 2005. Recognition of apoptotic cells by macrophages activates the peroxisome proliferator-activated receptor-gamma and attenuates the oxidative burst. Cell Death Differ Epub ahead of print.
18.
Inoue, C. N., H. G. Forster, and M. Epstein. 1995. Effects of lysophosphatidic acid, a novel lipid mediator, on cytosolic Ca2+ and contractility in cultured rat mesangial cells. Circ. Res. 77(5):888–896.PubMed
19.
Pebay, A., Y. Torrens, M. Toutant, J. Cordier, J. Glowinski, and M. Tence. 1999. Pleiotropic effects of lysophosphatidic acid on striatal astrocytes. Glia 28(1):25–33.PubMedCrossRef
20.
Fueller, M., D. A. Wang, G. Tigyi, and W. Siess. 2003. Activation of human monocytic cells by lysophosphatidic acid and sphingosine-1-phosphate. Cell. Signal 15(4):367–375.PubMedCrossRef
21.
Nakamoto, T., K. Yasuda, M. Yasuhara, T. Yoshimura, T. Kinoshita, T. Nakajima, H. Okada, A. Ikuta, and H. Kanzaki. 2005. Expression of the endothelial cell differentiation gene 7 (EDG-7), a lysophosphatidic acid receptor, in ovarian tumor. J. Obstet. Gynaecol. Res. 31(4):344–351.PubMedCrossRef
22.
Ohta, H., K. Sato, N. Murata, A. Damirin, E. Malchinkhuu, J. Kon, T. Kimura, M. Tobo, Y. Yamazaki, T. Watanabe, M. Yagi, M. Sato, R. Suzuki, H. Murooka, T. Sakai, T. Nishitoba, D. S. Im, H. Nochi, K. Tamoto, H. Tomura, and F. Okajima. 2003. Ki16425, a subtype-selective antagonist for EDG-family lysophosphatidic acid receptors. Mol. Pharmacol. 64(4):994–1005.PubMedCrossRef
23.
Baldini, P. M., P. De Vito, F. D’Aquilio, D. Vismara, F. Zalfa, C. Bagni, R. Fiaccavento, and P. Di Nardo. 2005. Role of atrial natriuretic peptide in the suppression of lysophosphatydic acid-induced rat aortic smooth muscle (RASM) cell growth. Mol. Cell. Biochem. 272(1–2):19–28.PubMedCrossRef
24.
Wang, L., E. Knudsen, Y. Jin, S. Gessani, and A. A. Maghazachi. 2004. Lysophospholipids and chemokines activate distinct signal transduction pathways in T helper 1 and T helper 2 cells. Cell. Signal. 16(9):991–1000.PubMed
25.
Rosskopf, D., W. Daelman, S. Busch, M. Schürks, K. Hartung, A. Kribben, M. C. Michel, and W. Siffert. 1998. Growth factor-like action of lysophosphatidic acid on human B lymphoblasts. Am. J. Physiol. 274(6):C1573–C1582.PubMed
26.
Martindale, J. L. and N. J. Holbrook. 2002. Cellular response to oxidative stress: signalling for suicide and survival. J. Cell. Physiol. 192(1):1–15.PubMedCrossRef
27.
Cathcart, M. K. 2004. Regulation of superoxide anion production by NADPH oxidase in monocytes/macrophages: contribution to atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 24(1):23–28.
28.
Anliker, B., and J. Chun. 2004. Cell surface in lysophospholipid signalling. Semin. Cell Dev. Biol. 15(5):457–465PubMedCrossRef
29.
Siess, W. 2002. Athero- and thrombogenic actions of lysophosphatidic acid and sphingosine-1-phosphate. Biochim. Biophys. Acta 1582:204–215PubMed
Metadata
Title
Activatory Properties of Lysophosphatidic Acid on Human THP-1 Cells
Authors
F. D’Aquilio
M. Procaccini
V. Izzi
V. Chiurchiu’
V. Giambra
F. Carotenuto
P. Di Nardo
P. M. Baldini
Publication date
01-12-2005
Published in
Inflammation / Issue 4-6/2005
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-006-9008-9

Other articles of this Issue 4-6/2005

Inflammation 4-6/2005 Go to the issue

OriginalPaper

Human Conjunctival Epithelial Cells Lack Lipopolysaccharide Responsiveness Due to Deficient Expression of MD2 but Respond After Interferon-γ Priming or Soluble MD2 Supplementation

OriginalPaper

Leukocytes in Complex Regional Pain Syndrome Type I

OriginalPaper

An Extract of the Medicinal Mushroom Agaricus blazei Murill Differentially Stimulates Production of Pro-inflammatory Cytokines in Human Monocytes and Human Vein Endothelial Cells in vitro

OriginalPaper

“In Vitro” Differences among (R) and (S) Enantiomers of Profens in their Activities Related to Articular Pathophysiology

OriginalPaper

Role of Interleukin-6 in Immune Complex Induced Models of Vascular Injury

OriginalPaper

Inhibition of Prostaglandin by Selective Cyclooxygenase 2 Inhibitors Accounts for Reduced Rat Leukocyte Migration
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits